JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.600
+0.010 (0.63%)
Jun 18, 2026, 11:18 AM HKT
Market Cap645.37M -8.5%
Revenue (ttm)315.65M +79.3%
Net Income-617.93M
EPS-1.49
Shares Out 405.90M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume195,500
Open1.600
Previous Close1.590
Day's Range1.550 - 1.690
52-Week Range1.570 - 6.440
Beta1.90
AnalystsStrong Buy
Price Target6.39 (+299.38%)
Earnings DateAug 28, 2026

About HKG:2126

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection (“relma-cel”) as a potential treatment for systemic lupus eryth... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 314
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2126
Full Company Profile

Financial Performance

In 2025, HKG:2126's revenue was 283.65 million, an increase of 79.28% compared to the previous year's 158.22 million. Losses were -555.29 million, -5.98% less than in 2024.

Financial numbers in CNY Financial Statements